Biofrontera Management
Management criteria checks 2/4
Biofrontera's CEO is Hermann Luebbert, appointed in May 2023, has a tenure of 2.33 years. total yearly compensation is $1.30M, comprised of 37% salary and 63% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth $147.81K. The average tenure of the management team and the board of directors is 2.5 years and 3.8 years respectively.
Key information
Hermann Luebbert
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 36.99% |
| CEO tenure | 2.3yrs |
| CEO ownership | 1.4% |
| Management average tenure | 2.5yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
FDA Approval And Product Expansion Will Unlock New Markets
FDA approval for expanded Ameluz use and restructuring agreements enhance margins, supporting future revenue growth through increased average sales size and reduced costs.Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues
Feb 27
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story
Sep 28Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce
Aug 09Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper
May 24Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%
Dec 30The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$17m |
| Mar 31 2025 | n/a | n/a | -US$12m |
| Dec 31 2024 | US$1m | US$482k | -US$18m |
| Sep 30 2024 | n/a | n/a | -US$13m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | US$733k | US$471k | -US$20m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$1m | US$475k | -US$640k |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$1m | US$18k | -US$38m |
Compensation vs Market: Hermann's total compensation ($USD1.30M) is above average for companies of similar size in the US market ($USD614.19K).
Compensation vs Earnings: Hermann's compensation has increased whilst the company is unprofitable.
CEO
Hermann Luebbert (69 yo)
Dr. Prof. Hermann Luebbert, Ph.D. is a Co-Founder of Biofrontera AG and served as its Chief Executive Officer since 1997 until December 13, 2021 and served as its Chairman of Management Board since 2000 un...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 2.3yrs | US$1.30m | 1.43% $ 147.8k | |
| Chief Financial Officer | 2.9yrs | US$832.63k | 0.82% $ 84.7k | |
| Senior Director of Finance & Principal Accounting Officer | no data | no data | no data | |
| Vice President of Scientific & Medical Affairs | 2.7yrs | no data | no data | |
| Senior Corporate Counsel | 6.7yrs | no data | no data | |
| Senior Vice President of Sales & Marketing | less than a year | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: BFRI's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 10.5yrs | US$1.30m | 1.43% $ 147.8k | |
| Independent Director | 3.8yrs | US$91.97k | no data | |
| Director | 2.2yrs | US$55.97k | no data | |
| Independent Director | 3.5yrs | US$74.97k | no data | |
| Independent Director | 3.8yrs | US$79.97k | no data |
Experienced Board: BFRI's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/30 22:10 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biofrontera Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Jonathan Aschoff | Roth Capital Partners |